Gyroscope is an ophthalmology company developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. Through targeted surgical delivery developed by its technology company, Orbit Biomedical, Gyroscope is uniquely poised to advance the fields of gene and cell therapy.

It is exploiting the convergence of breakthroughs in genetics and proprietary insights into the role of the complement system in AMD to develop a series of one-off gene therapy treatments for dry AMD and other chronic eye diseases.

The company was founded in 2016 with investments from Syncona and Cambridge Enterprise. Gyroscope is located in Stevenage at the Bioscience Catalyst.

Merger with Orbit medical in June 2019